Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children's Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Period	TotalRevenue
2016-12-31	$5.42M
2017-12-31	$154.58M
2018-12-31	$602.07M
2019-12-31	$380.83M
2020-12-31	$455.87M
2021-12-31	$612.40M
2022-12-31	$843.77M
2023-12-31	$1.14B
2024-12-31	$1.79B
2025-12-31	$1.86B

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SRPT	$16.67	-0.77%	3.09M
3
4
5

Sarepta Therapeutics Inc. (SRPT) Revenue History

Revenue Data

Get Sarepta Therapeutics Inc. Data in Excel

More SRPT Financial Data